
NYSEHealthcareMedical - Diagnostics & Research
Latest quote
$45.38
+$0.85 · +1.91%
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Latest quote
$45.38
+$0.85 · +1.91%
After-hours
$45.38
$0.00 · 0.00%
Oct 9, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Day range
Current $45.38
52-week range
Current $45.38
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
94
Deep Value
Sentiment
63
Bullish
Risk
41
Elevated Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Day range
Current $45.38
52-week range
Current $45.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.09B USD | 1.98B USD | 1.97B USD | 2.14B USD | 2.25B USD |
| Cost of goods sold | 798.5M USD | 1.01B USD | 731.62M USD | 756.96M USD | 800.84M USD |
| Gross profit | 1.29B USD | 967.35M USD | 1.23B USD | 1.38B USD | 1.45B USD |
| Research and development | 187.52M USD | 193.49M USD | 198.51M USD | 189.86M USD | 189.96M USD |
| Selling, general, and administrative | 583.67M USD | 564.36M USD | 579.17M USD | 603.95M USD | 584.47M USD |
| Operating expenses | 771.19M USD | 869.64M USD | 823.75M USD | 853.1M USD | 820.74M USD |
| Interest income | 64.32M USD | 68.02M USD | 78.99M USD | 32.76M USD | 9.56M USD |
| Interest expense | 33.26M USD | 43.84M USD | 53.41M USD | 58.36M USD | 54.48M USD |
| Depreciation and amortization | 193.75M USD | 203.27M USD | 205.34M USD | 208.4M USD | 214.93M USD |
| Operating income | 520.31M USD | 97.71M USD | 409.94M USD | 531.46M USD | 630.08M USD |
| Net income | 424.88M USD | 83.59M USD | 341.3M USD | 423.21M USD | 512.6M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$43.01
5.22% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 8, 2026 | 19:20 | — | — |
Stock split | Jan 29, 2025 | 35:36 | — | — |
Stock split | Jan 30, 2024 | 97:100 | — | — |
Stock split | Jan 25, 2017 | 481:500 | — | — |
Stock split | Jul 14, 2000 | 4:1 | — | — |
Stock split | Jul 16, 1999 | 2:1 | — | — |
Effective Jan 8, 2026
19:20
Effective Jan 29, 2025
35:36
Effective Jan 30, 2024
97:100
Effective Jan 25, 2017
481:500
Effective Jul 14, 2000
4:1
Effective Jul 16, 1999
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell Mid-Cap ETFIWR38.12M0.07%56.32B USD0.18%$109.82+0.87%
iShares Russell 1000 Value ETFIWD20.41M0.02%82.44B USD0.18%$253.54+0.61%
First Trust Health Care AlphaDEX FundFXH15.14M1.38%1.12B USD0.61%$130.15+1.37%
iShares Russell Mid-Cap Value ETFIWS13.93M0.09%15.21B USD0.23%$164.89+0.61%
Invesco Biotechnology & Genome ETFPBE11.94M2.91%412.43M USD0.59%$97.065+2.98%
iShares Systematic Alternatives Active ETFIALT6.33M0.08%7.56B USD0.99%$30.09+0.60%
iShares Russell 1000 ETFIWB6.32M0.01%49.4B USD0.15%$425.33+0.67%
iShares U.S. Healthcare ETFIYH5.97M0.15%3.99B USD0.37%$72.14+1.72%
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Value ETFIWD
First Trust Health Care AlphaDEX FundFXH
iShares Russell Mid-Cap Value ETFIWS
Invesco Biotechnology & Genome ETFPBE
iShares Systematic Alternatives Active ETFIALT
iShares Russell 1000 ETFIWB
iShares U.S. Healthcare ETFIYHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.